Novel blood test for early biomarkers of preeclampsia and Alzheimer’s disease

Abstract A non-invasive and sensitive blood test has long been a goal for early stage disease diagnosis and treatment for Alzheimer’s disease (AD) and other proteinopathy diseases. We previously reported that preeclampsia (PE), a severe pregnancy complication, is another proteinopathy disorder with...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Shibin Cheng, Sayani Banerjee, Lori A. Daiello, Akitoshi Nakashima, Sukanta Jash, Zheping Huang, Jonathan D. Drake, Jan Ernerudh, Goran Berg, James Padbury, Shigeru Saito, Brian R. Ott, Surendra Sharma
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/a0e8b71cb20e4e69945cd735b39330f0
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a0e8b71cb20e4e69945cd735b39330f0
record_format	dspace
spelling	oai:doaj.org-article:a0e8b71cb20e4e69945cd735b39330f02021-12-02T17:06:09ZNovel blood test for early biomarkers of preeclampsia and Alzheimer’s disease10.1038/s41598-021-95611-52045-2322https://doaj.org/article/a0e8b71cb20e4e69945cd735b39330f02021-08-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-95611-5https://doaj.org/toc/2045-2322Abstract A non-invasive and sensitive blood test has long been a goal for early stage disease diagnosis and treatment for Alzheimer’s disease (AD) and other proteinopathy diseases. We previously reported that preeclampsia (PE), a severe pregnancy complication, is another proteinopathy disorder with impaired autophagy. We hypothesized that induced autophagy deficiency would promote accumulation of pathologic protein aggregates. Here, we describe a novel, sensitive assay that detects serum protein aggregates from patients with PE (n = 33 early onset and 33 late onset) and gestational age-matched controls (n = 77) as well as AD in both dementia and prodromal mild cognitive impairment (MCI, n = 24) stages with age-matched controls (n = 19). The assay employs exposure of genetically engineered, autophagy-deficient human trophoblasts (ADTs) to serum from patients. The aggregated protein complexes and their individual components, including transthyretin, amyloid β-42, α-synuclein, and phosphorylated tau231, can be detected and quantified by co-staining with ProteoStat, a rotor dye with affinity to aggregated proteins, and respective antibodies. Detection of protein aggregates in ADTs was not dependent on transcriptional upregulation of these biomarkers. The ROC curve analysis validated the robustness of the assay for its specificity and sensitivity (PE; AUC: 1, CI: 0.949–1.00; AD; AUC: 0.986, CI: 0.832–1.00). In conclusion, we have developed a novel, noninvasive diagnostic and predictive assay for AD, MCI and PE.Shibin ChengSayani BanerjeeLori A. DaielloAkitoshi NakashimaSukanta JashZheping HuangJonathan D. DrakeJan ErnerudhGoran BergJames PadburyShigeru SaitoBrian R. OttSurendra SharmaNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-15 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Shibin Cheng Sayani Banerjee Lori A. Daiello Akitoshi Nakashima Sukanta Jash Zheping Huang Jonathan D. Drake Jan Ernerudh Goran Berg James Padbury Shigeru Saito Brian R. Ott Surendra Sharma Novel blood test for early biomarkers of preeclampsia and Alzheimer’s disease
description	Abstract A non-invasive and sensitive blood test has long been a goal for early stage disease diagnosis and treatment for Alzheimer’s disease (AD) and other proteinopathy diseases. We previously reported that preeclampsia (PE), a severe pregnancy complication, is another proteinopathy disorder with impaired autophagy. We hypothesized that induced autophagy deficiency would promote accumulation of pathologic protein aggregates. Here, we describe a novel, sensitive assay that detects serum protein aggregates from patients with PE (n = 33 early onset and 33 late onset) and gestational age-matched controls (n = 77) as well as AD in both dementia and prodromal mild cognitive impairment (MCI, n = 24) stages with age-matched controls (n = 19). The assay employs exposure of genetically engineered, autophagy-deficient human trophoblasts (ADTs) to serum from patients. The aggregated protein complexes and their individual components, including transthyretin, amyloid β-42, α-synuclein, and phosphorylated tau231, can be detected and quantified by co-staining with ProteoStat, a rotor dye with affinity to aggregated proteins, and respective antibodies. Detection of protein aggregates in ADTs was not dependent on transcriptional upregulation of these biomarkers. The ROC curve analysis validated the robustness of the assay for its specificity and sensitivity (PE; AUC: 1, CI: 0.949–1.00; AD; AUC: 0.986, CI: 0.832–1.00). In conclusion, we have developed a novel, noninvasive diagnostic and predictive assay for AD, MCI and PE.
format	article
author	Shibin Cheng Sayani Banerjee Lori A. Daiello Akitoshi Nakashima Sukanta Jash Zheping Huang Jonathan D. Drake Jan Ernerudh Goran Berg James Padbury Shigeru Saito Brian R. Ott Surendra Sharma
author_facet	Shibin Cheng Sayani Banerjee Lori A. Daiello Akitoshi Nakashima Sukanta Jash Zheping Huang Jonathan D. Drake Jan Ernerudh Goran Berg James Padbury Shigeru Saito Brian R. Ott Surendra Sharma
author_sort	Shibin Cheng
title	Novel blood test for early biomarkers of preeclampsia and Alzheimer’s disease
title_short	Novel blood test for early biomarkers of preeclampsia and Alzheimer’s disease
title_full	Novel blood test for early biomarkers of preeclampsia and Alzheimer’s disease
title_fullStr	Novel blood test for early biomarkers of preeclampsia and Alzheimer’s disease
title_full_unstemmed	Novel blood test for early biomarkers of preeclampsia and Alzheimer’s disease
title_sort	novel blood test for early biomarkers of preeclampsia and alzheimer’s disease
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/a0e8b71cb20e4e69945cd735b39330f0
work_keys_str_mv	AT shibincheng novelbloodtestforearlybiomarkersofpreeclampsiaandalzheimersdisease AT sayanibanerjee novelbloodtestforearlybiomarkersofpreeclampsiaandalzheimersdisease AT loriadaiello novelbloodtestforearlybiomarkersofpreeclampsiaandalzheimersdisease AT akitoshinakashima novelbloodtestforearlybiomarkersofpreeclampsiaandalzheimersdisease AT sukantajash novelbloodtestforearlybiomarkersofpreeclampsiaandalzheimersdisease AT zhepinghuang novelbloodtestforearlybiomarkersofpreeclampsiaandalzheimersdisease AT jonathanddrake novelbloodtestforearlybiomarkersofpreeclampsiaandalzheimersdisease AT janernerudh novelbloodtestforearlybiomarkersofpreeclampsiaandalzheimersdisease AT goranberg novelbloodtestforearlybiomarkersofpreeclampsiaandalzheimersdisease AT jamespadbury novelbloodtestforearlybiomarkersofpreeclampsiaandalzheimersdisease AT shigerusaito novelbloodtestforearlybiomarkersofpreeclampsiaandalzheimersdisease AT brianrott novelbloodtestforearlybiomarkersofpreeclampsiaandalzheimersdisease AT surendrasharma novelbloodtestforearlybiomarkersofpreeclampsiaandalzheimersdisease
_version_	1718381747450675200

Novel blood test for early biomarkers of preeclampsia and Alzheimer’s disease

Ejemplares similares